FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
708 letters match. Newest first.
-
DrugsEverlaan Organics, Inc. dba Maple Organics
FDA warns Maple Organics over OTC drug CGMP failures, unapproved new drugs, and misbranding.
High risk -
DrugsABBE Laboratories, Inc.
FDA warns ABBE Laboratories over manufacturing failures for over-the-counter topical drugs, including ingredient testing.
High risk -
DevicesSpectra Therapy, LLC
FDA warns Spectra Therapy over LASERwrap infrared lamp device quality-system violations and unapproved disease-treatment claims.
High risk -
DrugsGussyup LLC dba Private Label Grooming
FDA found Gussyup LLC, a Henderson, Nevada OTC drug maker, lacking quality oversight and ingredient identity testing; company stopped drug production.
High risk -
DrugsOasis Medical, Inc.
FDA cites Oasis Medical for current good manufacturing practice violations in sterile ophthalmic drugs, including particulate contamination and unresolved sterility failures.
High risk -
DrugsShiva Analyticals Private Limited
FDA warned Shiva Analyticals, an Indian contract drug testing lab, that inadequate OOS investigations and data integrity failures adulterated tested drugs.
High risk -
DrugsKabana Skin Care LLC
Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.
High risk -
DrugsGlenmark Pharmaceuticals Limited
FDA warns Glenmark over unresolved dissolution failures and inadequate investigations at its Pithampur, India drug plant.
High risk -
DrugsMedical Chemical Corporation
FDA warned Medical Chemical Corp over manufacturing violations, unapproved Tincture Green Soap, and improper drug listing.
High risk -
DrugsNature’s Fusions LLC
FDA cited Nature's Fusions for over-the-counter hand sanitizer manufacturing with inadequate stability, component and finished-product testing, and water controls.
High risk -
DrugsDaewoo Pharmaceutical Co., Ltd.
FDA warns Daewoo Pharmaceutical over CGMP (manufacturing quality rules) failures at Busan plant; company suspended production.
High risk -
DrugsLibby Laboratories, Inc.
FDA warned Libby Laboratories of Berkeley, California, that its drug manufacturing violated CGMP, including releasing a hospital antiseptic without microbial testing.
High risk -
DrugsXtreme Tools International, Inc.
FDA warned Xtreme Tools International after an inspection found manufacturing-rule failures for OTC topical drugs, including missing ingredient and batch testing.
High risk -
DrugsDynamic Blending Specialists, Inc.
FDA cited Dynamic Blending Specialists for manufacturing failures in OTC drugs and an unapproved, misbranded oral antiseptic.
High risk -
FoodVoehlganic Farm LLC
FDA warned Voehlganic Farm LLC that its shell eggs are adulterated because it lacked a Salmonella Enteritidis prevention plan and testing.
High risk -
DrugsExela Pharma Sciences, LLC
Exela Pharma Sciences failed CGMP (current good manufacturing practice) for sterile injectable drugs, including invalidated sterility-media tests and inaccurate microbiology records.
High risk -
BiologicsInVia Fertility Specialists, PLLC
FDA warned InVia Fertility Specialists over reproductive tissue donor eligibility and missing infectious disease testing.
High risk -
DrugsHealwell Homeo Private Limited
FDA warns Healwell Homeo over pest-infested drug storage and manufacturing violations.
High risk -
DrugsPushclean Technology Plastik Sanayi Ve Ticaret Ltd. Sirketi
FDA warns Turkish OTC drug wipe maker Pushclean over missing finished-product and component testing.
High risk -
DevicesAju Pharm Co., Ltd.
FDA warns Aju Pharm over unvalidated Fixone suture anchors and multiple quality-system failures.
High risk -
DrugsHorizon Tool Inc.
FDA warns Horizon Tool over manufacturing-rule violations for AllShield E2 Sanitizing Hand Soap.
High risk -
DrugsLaboratoire Druide Inc.
FDA warned Laboratoire Druide that its OTC drugs are adulterated because of inadequate glycerin identity testing, system validation and cleaning.
High risk -
DrugsAmish Origins Management, LLC
FDA warned Amish Origins over manufacturing quality failures and unapproved or misbranded OTC pain relief and lip balm products.
High risk -
DrugsAmerican Behavioral Research Institute, LLC
FDA warned American Behavioral Research Institute for running a 40-subject Relaxium sleep study without an IND, treating a supplement as a drug.
High risk -
DrugsCTK OTC Laboratories LLC formerly FMK LABS, Inc.
CTK OTC Laboratories, formerly FMK Labs, failed to investigate out-of-spec results and validate processes for OTC drugs, including sunscreens.
High risk -
DrugsEvi Labs LLC
FDA warns Evi Labs over OTC drug manufacturing failures, including an antiperspirant lot above the aluminum chlorohydrate limit.
High risk -
DrugsZhejiang Easyclean Daily Chemical Co., Ltd
FDA warned Zhejiang Easyclean Daily Chemical that its OTC drugs lacked required testing and manufacturing controls.
High risk -
DrugsHuangshi Hygienic Material Medicine Co., Ltd.
Huangshi Hygienic Material Medicine released U.S. drugs without identity and strength testing and lacked stability data for labeled expiration dates.
High risk -
FoodGolden Grains Bakery
FDA warns Golden Grains Bakery over repeated preventive-control failures for RTE Blender Bombs, including metal detection and Listeria risks.
High risk -
DevicesNeuroSync, Inc.
FDA warned NeuroSync, Inc. that its EYE-SYNC eye-assessment device was adulterated by design control, CAPA, supplier and acceptance failures, plus unreported correction and missing UDI.
High risk -
DrugsProduct Society LLC
FDA says Product Society LLC, an OTC drugmaker in North Hollywood, California, skipped identity testing for toxic DEG/EG and process validation.
High risk -
DrugsWuxi Medical Instrument Factory Co., Ltd.
FDA warns Wuxi Medical Instrument Factory over insanitary conditions and manufacturing failures for sterile drugs.
High risk -
DrugsNWL Netherlands Services B.V.
FDA cites NWL Netherlands drug plant for inadequate microbial investigations, missing component identity testing, and weak lab data controls.
High risk -
BiologicsSkye Biologics Holdings LLC
FDA warns Skye Biologics its umbilical cord-derived BioECM products are unapproved drugs and unlicensed biologics, made with serious manufacturing (CGMP) failures.
High risk -
DrugsNingbo Riway Industrial Co., Ltd.
Ningbo Riway Industrial, an OTC drug maker in China, was cited for manufacturing-practice failures and unapproved antiseptic wipes.
High risk -
DrugsMentha & Allied Products Private Ltd.
FDA warns Mentha & Allied Products of CGMP failures that leave its APIs adulterated.
High risk -
DrugsShantou S.E.Z. Baojie Industry Co., Ltd.
FDA warns Shantou S.E.Z. Baojie Industry over inadequate CGMP and component testing for OTC drug products, leading to Import Alert 66-40.
High risk -
DrugsTaizhou Jingshang Cosmetics Technology Co., Ltd.
FDA warns Taizhou Jingshang Cosmetics Technology over current good manufacturing practice failures in over-the-counter drugs, including missing identity tests for high-risk ingredients.
High risk -
DrugsBioAsia Worldwide Sdn Bhd
FDA warned BioAsia Worldwide over current good manufacturing practice violations for OTC drugs.
High risk -
DrugsCosco International, Inc.
FDA warned Cosco International over nonprescription drug manufacturing failures and unapproved drug products.
High risk -
DrugsDyno Manufacturing, Inc.
Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.
High risk -
DrugsBEO Pharma Inc. dba BEO Pharmaceuticals Inc.
FDA cited BEO Pharma for manufacturing quality violations, including missing identity testing of high-risk drug ingredients and releasing a batch before microbial testing.
High risk -
DrugsPMS4PMS, LLC
FDA warns PMS4PMS of Clarence, NY, over CGMP failures and an unapproved menstrual cramp relief cream.
High risk -
DrugsNubratori, Inc. dba Nubratori Rx
FDA cited Nubratori Rx, a sterile compounding outsourcing facility, for insanitary conditions and manufacturing quality failures that may contaminate its drug products.
High risk -
DrugsYangzhou Sion Commodity Co., Ltd.
FDA warned Yangzhou Sion Commodity over drug manufacturing failures, including untested high-risk ingredients and unreliable lab records.
High risk -
DevicesDexcom, Inc.
FDA warned Dexcom over quality-system and design-control failures for G6 and G7 glucose monitors, including an unapproved sensor component change.
High risk -
DrugsHangzhou Glamcos Biotech Co., Ltd.
Hangzhou Glamcos Biotech’s OTC antibacterial wipes had CGMP violations and were unapproved and misbranded, FDA says.
High risk -
DrugsAdvanced Pharmaceutical Technology
FDA warns Advanced Pharmaceutical Technology over drug manufacturing quality failures, sterility controls, and unapproved drugs.
High risk -
DrugsNeva Global Grup Sanayi Ic Ve Dis Ticaret Anonim Sirketi
FDA warns Turkish OTC drug maker Neva Global over inadequate component testing, process validation, stability, and quality oversight.
High risk -
DrugsInternational Laboratories Corp
FDA warned International Laboratories Corp, a Thai drug manufacturer, over fabricated lab records and inadequate CGMP controls.
High risk